Hepatitis-C-Harvoni

Contact KTMC
Free Consultation
* denotes required fields
I agree to the KTMC disclaimer
I would like to receive new case alerts by email

Kessler Topaz Meltzer & Check, LLP Investigates Potential Class Action Lawsuits On Behalf of Chronic Hepatitis C Patients

Kessler Topaz Meltzer & Check, LLP (“Kessler Topaz”) is investigating potential class action lawsuits against certain health insurance providers for their unlawful denial of coverage and refusal to pay for Harvoni or a related prescription drug – a medically necessary treatment which can effectively cure chronic Hepatitis C (“CHC”).

Specifically, Kessler Topaz is investigating whether Hepatitis C patients were denied Harvoni or a related prescription drug treatment on the grounds that their liver was not “damaged enough” to warrant treatment.

About Hepatitis C and Harvoni

Hepatitis C is a widespread contagious disease that can lead to severe liver damage, cancer, and even death.  In October 2014, the United States Food and Drug Administration approved Harvoni, a prescription drug that can effectively cure Hepatitis C. 

Harvoni is the first drug approved for the treatment of CHC that does not require combination with other drugs, and can effectively cure CHC in the vast majority of those affected.

Alleged Unlawful Conduct

Notwithstanding the life-saving treatment offered to CHC patients by Harvoni or a related prescription drug, certain health insurance providers may have unlawfully limited CHC patients’ access to medically necessary treatment by developing arbitrary coverage criteria. 

Below is a list of the health insurance providers that Kessler Topaz is currently investigating:

• Centene Health
• Kaiser Health
• Highmark

If you or someone you know was denied Harvoni or a related prescription drug treatment, and would like to learn more about our investigation, please fill out our online form, or contact us today at 888-299-7706 or by email at info@ktmc.com.